More disappointment for Orphazyme as FDA rejects Niemann Pick C application

The FDA have rejected an application for marketing authorization for Orphazyme's main drug candidate, arimoclomol, as a treatment for metabolic disease Niemann Pick C. The authority wants more data.

Photo: Orphazyme/PR

The bad news just keeps on coming for Orphazyme.

The biotech company's key candidate, arimoclomol, got the thumbs down from the US Food and Drug Administration (FDA) as a treatment for Niemann Pick type C, also known as NPC.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs